Last reviewed · How we verify

Elcelyx Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Elcelyx Therapeutics, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Met DR Met DR marketed
Met IR Met IR marketed Biguanide AMP-activated protein kinase (AMPK) Endocrinology / Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bristol-Myers Squibb · 1 shared drug class
  2. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  3. Eli Lilly and Company · 1 shared drug class
  4. Ente Ospedaliero Ospedali Galliera · 1 shared drug class
  5. First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Janssen Research & Development, LLC · 1 shared drug class
  8. AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Elcelyx Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Elcelyx Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/elcelyx-therapeutics-inc. Accessed 2026-05-16.

Related